<DOC>
	<DOCNO>NCT01170091</DOCNO>
	<brief_summary>Safety Effect Mirapex ( Pramipexole ) tablet among Korean Restless Legs Syndrome Patients : An Open-Label , Postmarketing Surveillance Study</brief_summary>
	<brief_title>Safety Effect Mirapex ( Pramipexole ) Tablet Among Korean RLS</brief_title>
	<detailed_description>Study Design :</detailed_description>
	<mesh_term>Restless Legs Syndrome</mesh_term>
	<mesh_term>Pramipexole</mesh_term>
	<criteria>Inclusion criterion : 1 . Moderate severe Primary Restless Legs Syndrome 2 . Male female patient age least 18 year Exclusion criterion : 1 . Any contraindication accord Basic Product Information ( Company Core Data Sheet ) local Labelling ; hypersensitivity pramipexole excipients . 2 . Ongoing treatment Mirapex 3 . Pregnant breastfeed woman 4 . Concomitant pharmacologic treatment dopaminergic drug ( include Ldopa ) 5 . Secondary RLS</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
</DOC>